DigestRedComo funciona
Red
/
Empresas
Ep
No verificado

Epicrispr Biotechnologies

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
08/01/2026
Eventos
Industria
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Web y redes sociales
Asociaciones/Profesionales
Salud
Finanzas
Medicina - Varios
Farmacéutica
Biotecnología
Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
05/08/2025
Sanidad
Ciencia
Farmacéutica
Ir de compras
Biotecnología
Infancia
Medicina - Varios
Higiene alimentaria
Salud
Industria
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
12/05/2025
Eventos
Ciencia
Biotecnología
Farmacéutica
Salud
Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
05/05/2025
Eventos
Biotecnología
Higiene alimentaria
Sanidad
Salud
Farmacéutica
Ciencia
Medicina - Varios
Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
23/04/2025
Industria
Material médico sanitario
Salud
Técnica
Biotecnología
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
03/04/2025
Industria
Biotecnología
Higiene alimentaria
Sanidad
Salud
Farmacéutica
Ciencia
Medicina - Varios
Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0
26/03/2025
Ciencia
Sanidad
Asociaciones/Profesionales
Farmacéutica
Biotecnología
Medicina - Varios
Higiene alimentaria
Salud
Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
Fuente
Epicrispr Biotechnologies
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0